COMMUNIQUÉS West-GlobeNewswire

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
23/10/2026
>90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 12 weeks ~33-day half-life NAVIGATE-2 Phase 2 trial enrolling, with initial data expected in the [...]
Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders
23/10/2026
Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluated Additional data highlighted the challenges of managing hyperphosphatemia and the morbidity [...]
ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
23/10/2026
First-in-human data for ARR-217 selected as a late-breaking oral presentation ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program NEWTOWN SQUARE, Pa., [...]
Beyond Elizabeth Holmes: Ryan El Hosseiny Thanks Nathan Fielder for Shining a Light on Cancer Research
23/10/2026
MIAMI, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Featured as “The Billboard Guy” in Nathan Fielder's documentary, You Can See Everything , biochemist, entrepreneur and Just Blood founder Ryan El Hosseiny welcomes the spotlight [...]
SERB Pharmaceuticals Announces Positive Results from the Post-Authorisation Efficacy Study of Idefirix® (imlifidase) Presented at ASN Kidney Week 2026
23/10/2026
Study met its primary objective: 1-year graft failure-free survival at 12 months post-transplant was 90%, which is clinically meaningful Graft and patient survival were 92% and 98%, respectively Idefirix ® was generally [...]
Le CHMP recommande l’approbation de TALVEY®▼ (talquetamab) de Johnson & Johnson, en association avec le daratumumab, dans une ligne de traitement plus précoce du myélome multiple en rechute/réfractaire
23/10/2026
Sous réserve de son approbation, l’association TALVEY ® et daratumumab constituerait la seule association thérapeutique comprenant un anticorps bispécifique ciblant le GPRC5D dans le traitement du myélome multiple en [...]
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
23/10/2026
Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all prespecified patient [...]
NeOnc Breaks Through Key Levels, as Brain-Cancer Stock’s Catalysts Continue
23/10/2026
Price barriers are falling, as improving technicals meet a string of clinical, international, and regulatory milestones with November 17’s FDA meeting next on the calendar. DENVER, Oct. 23, 2026 (GLOBE NEWSWIRE) -- ( [...]
Collaboration entre Fortrea et Omico pour faire progresser le développement de médicaments oncologiques basés sur des biomarqueurs
23/10/2026
Cette collaboration vise à améliorer la planification des essais cliniques et à élargir l’accès des patients aux études ciblées par biomarqueurs en Australie Points clés Cette collaboration vise à accélérer la recherche [...]
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
23/10/2026
Company Announcement COPENHAGEN, Denmark; October 23, 2026 Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart [...]
Idorsia presents outstanding results with daridorexant in children and adolescents with insomnia and an expanding body of evidence in adults at Sleep Europe 2026
23/10/2026
Daridorexant, a dual orexin receptor antagonist, is the first investigational treatment in its class to demonstrate positive results in pediatric insomnia disorder, an area in which significant unmet needs remain for [...]
Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile
23/10/2026
Remibrutinib achieved significant and clinically meaningful reduction in relapses vs. teriflunomide, to approximately 1 relapse every 13 years, without the need for chronic B-cell depletion¹˒ ² MRI disease activity [...]
Le KFSH réduit le délai d’attente pour un rendez-vous d’échocardiographie de 126 jours à un seul
23/10/2026
RIYAD, Arabie saoudite, 23 oct. 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital and Research Centre (KFSH) a réduit le délai d’attente pour le premier rendez-vous d’échocardiographie disponible dans son [...]
Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner
23/10/2026
- The presenter, Dr. Roy-Chaudhury said, “These results give the nephrology community a strong reason to rethink our approach to access decisions for women and, once approved by the FDA, to consider the ATEV as a [...]
Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026
23/10/2026
Quality of life remained stable during neoadjuvant treatment with efti, pembrolizumab and radiotherapy, with statistically significant improvement after surgery SYDNEY, AUSTRALIA, Oct. 23, 2026 (GLOBE NEWSWIRE) -- [...]
KFSH Advances Gene Therapy for Sickle Cell Disease Using Patients’ Own Modified Stem Cells
23/10/2026
RIYADH, Saudi Arabia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) is advancing gene therapy for sickle cell disease through a 2026 clinical trial that uses the patient’s [...]
Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026
23/10/2026
Single-dose miv-cel continues to demonstrate promising clinical benefit in progressive multiple sclerosis, achieving robust CAR T-cell penetration in the central nervous system (CNS) and improving disability scores [...]
How Peptide Conjugate Developability Is Shaped Before a Candidate Is Nominated
23/10/2026
Of the 106 peptide and nanobody drug conjugates in active development, roughly 63% are still preclinical, which places many of the decisions that shape manufacturability in the design phase. Cyclization, lipidation, [...]
Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma
23/10/2026
62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 Analysis Median Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-up Oral Presentation at the [...]

Pages